http://www.raredr.com/conferences/aspho2017/itp-in-children
Immune Thrombocytopenia Treatment in Children

James Bussel, M.D.



James Bussel, MD, of Weill Cornell Medicine talks about immune thrombocytopenia (ITP) in children, its current treatment and some of the data presented at ASPHO's 20th Annual Meeting held in Montreal, Canada. 
 
ITP is a rare blood disorder that results in abnormally low platelet levels that leads to increase risk of bleeding. Approximately 5 in 100,000 children each year get ITP and of those, approximately 25% have the condition for over 1 year and are considered chronic ITP pediatric patients.
 
In 2015, Promacta (eltrombopag) was approved for the treatment of ITP children 6 years and older. The other ITP orphan drug currently approved for adults [Nplate (romiplostim)] is expected to be also be approved for the children with ITP.

References

Bussel JB, Tarantino MD, Blanchette VS. Safety and efficacy of long-term open-label dosing of subcutaneous romiplostim in children with immune thrombocytopenia (ITP). Presented at ASPHOs 20th Annual Meeting; Montreal, Canada; April 26-29, 2017.
 
Grainger J, Bussel JB, Cooper N. A single-arm, open-label, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia (ITP). Presented at ASPHOs 20th Annual Meeting; Montreal, Canada; April 26-29, 2017.
 
Bussel JB, Keefe PJ, Rocha AM. Safety and efficacy of eltrombopag (EPAG) at doses up to 150 mg/day in children with chronic immune thrombocytopenia (cIPT) who did not achieve target platelet counts with 75 mg/day dose. Presented at ASPHOs 20th Annual Meeting; Montreal, Canada; April 26-29, 2017.
Printer Printing...
$content$